Grifols S A : November 9, 2020Grifols consolidates its Hospital Division as a reference in innovative solutions with the acquisition of the 49% stake in MedKeeper

Grifols consolidates its Hospital Division as a reference in innovative solutions with the acquisition of the 49% stake in MedKeeper

• In 2018, Grifols acquired a 51% stake in the U.S. firm MedKeeper. Now, certain options are exercised and Grifols acquires the remaining 49% stake for USD 60.2 million
• MedKeeper is a technology firm that develops and markets mobile and web- based technology solutions, which are used by hundreds of hospitals and medical centers to enhance the efficiency, safety and compliance of key operational processes
• MedKeeper's features complement and strengthen Pharmatech, the Hospital Division's main business line, and will help boost its presence in the U.S. market

Barcelona, November 9, 2020. - Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the top three leader in the production of plasma-derived medicines and research pioneer on alternative therapies aimed at advancing scientific and social progress, today announced the acquisition of the remaining 49% share of Goetech LLC, whose trade name is MedKeeper, in exchange for a total price of USD 60.2 million. No additional financing will be required.

Since 2018, Grifols has owned a 51% equity stake of this U.S.-based technology firm, dedicated to developing and commercializing mobile and web-based technology solutions that enhance quality assurance standards and operational productivity, as well as monitor and track compounding activities. MedKeeper solutions are used by hundreds of hospitals and medical centers to increase patient safety.

Grifols continues to move forward with its strategic plans to drive long-term sustainable growth in all of its divisions.

In the case of the Hospital Division, MedKeeper's attributes complement and strengthen Pharmatech, its core business line. The transaction also boosts the division's international expansion and footprint in the U.S. market.

Grifols is a global reference in hospital pharmacy solutions, helping ensure the safety of patients and healthcare professionals by developing and distributing equipment and specialty technology to automate and control key hospital processes.

Page 1 of 3

Investor contact:

Investor [e-mail] [e-mail]

Phone number: [phone]

Media contacts:
Spain:	International:
Raquel Lumbreras	Brad Pick
[e-mail]	[e-mail]
Borja Gómez	Grifols Corporate Communications
[e-mail]
Duomo Comunicación - Grifols PR office
Tel. [phone]

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies

• develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2019, Grifols' economic impact in its core countries of operation was EUR 8.5 billion. The company also generated 148,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex- 35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing

Page 2 of 3

this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.

Page 3 of 3